clinical trial · NCT05660538
Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN)
Vertex Pharmaceuticals Incorporated·phase2·completed·n = 194
Diabetic Peripheral NeuropathySuzetriginePregabalinPlacebo (matched to SUZ)Placebo (matched to pregabalin)
brief summary
The purpose of this study is to evaluate the efficacy and safety of VX-548 doses in treating Painful DPN.
started
Dec 20, 2022
primary completion
Oct 12, 2023
completion
Oct 25, 2023
last updated
Jul 1, 2025
official title
A Phase 2, Randomized, Double-blind, Active-controlled, Dose-ranging, Parallel-design Study of the Efficacy and Safety of VX-548 in Subjects With Painful Diabetic Peripheral Neuropathy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol